ArticleJournal of pharmacokinetics and pharmacodynamics2008
A nonlinear mixed effects IVIVC model for multi-release drug delivery systems.
Article in Journal of pharmacokinetics and pharmacodynamics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Population in vitro-in vivo correlation model for pramipexole slow-release oral formulations.Pharmaceutical research · 2010Trial
- Development of a Clinically Relevant Dissolution Method for Metaxalone Immediate Release Formulations Based on an IVIVC Model.Pharmaceutical research · 2018Article
- In vitro- in vivo correlation's dissolution limits setting.Pharmaceutical research · 2014Article
- A time scaling approach to develop an in vitro-in vivo correlation (IVIVC) model using a convolution-based technique.Journal of pharmacokinetics and pharmacodynamics · 2011Article
- A population approach to in vitro-in vivo correlation modelling for compounds with nonlinear kinetics.Journal of pharmacokinetics and pharmacodynamics · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this analysis was the development of an IVIVC model, which involves a convolution step as described by O'Hara et al. and to describe a dual-release system: a controlled release formulation, which contains an initial immediate release element. Four formulations of Galantamine were used to test this modelling technique and a level A IVIVC, which meets the FDA criteria for internal and external validation, was successfully developed.
Indexed as
Identifiers
18780164What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.